#### Resistance Associated Mutations in HCV Patients Failing ...

https://pubmed.ncbi.nlm.nih.gov/33453702

Currently, treatment of chronic hepatitis C is based on a combination of direct-acting antiviral agents (DAAs) which achieve HCV clearance in more than 95% of patients. Despite this high rate of cure, treatment failures can occur in about 3-5% of treated patients. Resistance associated substitutions (RAS) are commonly detected after virological failure, although their role in real-life DAA failures is ...

# Hepatitis C virus drug resistance associated substitutions ... https://pubmed.ncbi.nlm.nih.gov/29525636

The natural presence of resistance associated substitutions (RASs), as well as their rapid emergence during incomplete drug-pressure, are intrinsic characteristics of HCV that greatly affect treatment outcome and the chances to achieve a virolgical cure.

Cited by: 126 Author: Maria C. Sorbo, Valeria Cento, Velia C. Di...
Publish Year: 2018

### Hepatitis C Virus Resistance Testing in Genotype 1: The ...

https://pubmed.ncbi.nlm.nih.gov/28480743

Conclusions: Baseline resistance testing was used for decisional support for 3 clinical scenarios in patients with HCV genotype 1 infection at the time of manuscript submission. Pending the approval of 2 new direct-acting antiviral regimens in the third quarter of 2017, the rapidly evolving HCV treatment guidelines will likely reflect a decreased clinical utility for resistance testing.

Cited by: 7 Author: Suzanne Molino, Suzanne Molino, Michel...
Publish Year: 2017


# How much of a problem is resistance in treating hepatitis C? https://www.ncbi.nlm.nih.gov/pubmed/27673712


These resistance-associated substitutions (RASs) may exist prior to treatment, and are associated with, but do not inevitably result in, treatment failure. The most important RASs with current regimens occur in the NS5A protein of viral variants, which may persist for years after treatment.

Cited by: 4 Author: Daniel M. Forton

Publish Year: 2016

Hepatitis C virus drug resistance associated substitutions ...







#### Hepatitis C virus failure to treatment: Clinical utility of testing resist





Q

ALL

**IMAGES** 

VIDEOS

11,400 Results

Any time \*

#### Hepatitis C virus drug resistance associated substitutions ...

https://www.sciencedirect.com/science/article/pii/S1368764618300128

Mar 01, 2018 · The ability of some RASs to confer resistance to multiple DAAs, as well as the potential development of complex multiclass-resistance patterns at failure, makes HCV resistance testing an important diagnostic tool to tailor second line therapy and improve chances of virological success, especially when simultaneously performed on NS3, NS5A and NS5B (Vigano et al., 2017). The present manuscript aims to assists virologist and clinicians in the interpretation of HCV resistance testing ...

Cited by: 142 Author: Maria C. Sorbo, Valeria Cento, Velia C. Di...

Publish Year: 2018

### Hepatitis C virus drug resistance associated substitutions ...

https://pubmed.ncbi.nlm.nih.gov/29525636

The natural presence of resistance associated substitutions (RASs), as well as their rapid emergence during incomplete drug-pressure, are intrinsic characteristics of HCV that greatly affect treatment outcome and the chances to achieve a virolgical cure. To date, a high number of RASs in NS3, NS5A, and NS5B have been associated in vivo and/or ...

Cited by: 142 Author: Maria C. Sorbo, Valeria Cento, Velia C. Di...

Publish Year: 2018

## Hepatitis C Virus Resistance Testing in Genotype 1: The ...

https://pubmed.ncbi.nlm.nih.gov/28480743

Objective: To review the role and utility of baseline resistance testing with currently available and pipeline genotype 1 hepatitis C virus (HCV) treatment. Data sources: Authors reviewed liver meeting abstracts for data on currently-available and pipeline genotype 1 retreatment regimens from January 1, 2015, to March 23, 2017. Additional trials were identified from a review of ...

Cited by: 7 Author: Suzanne Molino, Suzanne Molino, Michel...

Publish Year: 2017

## Complex Pattern of Resistance-Associated Substitutions of ...

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0165339 •

Oct 24, 2016 · Backgrounds & Aims We aimed to clarify the characteristics of resistance-associated substitutions (RASs) after treatment failure with NS5A inhibitor, daclatasvir (DCV) in combination with